MX2020008110A - Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma. - Google Patents
Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma.Info
- Publication number
- MX2020008110A MX2020008110A MX2020008110A MX2020008110A MX2020008110A MX 2020008110 A MX2020008110 A MX 2020008110A MX 2020008110 A MX2020008110 A MX 2020008110A MX 2020008110 A MX2020008110 A MX 2020008110A MX 2020008110 A MX2020008110 A MX 2020008110A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- salt
- pyrazolo
- pyrimidine compound
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Una sal del compuesto representado por la fórmula (I) y cristales de la misma que tienen el potencial de usarse como sustancias farmacológicas para productos farmacéuticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018031646 | 2018-02-26 | ||
| PCT/JP2019/006850 WO2019163956A1 (ja) | 2018-02-26 | 2019-02-22 | ピラゾロ［１，５－ａ］ピリミジン化合物の塩およびその結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008110A true MX2020008110A (es) | 2020-11-06 |
Family
ID=67687243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008110A MX2020008110A (es) | 2018-02-26 | 2019-02-22 | Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11312720B2 (es) |
| EP (1) | EP3760631B1 (es) |
| JP (1) | JP7257376B2 (es) |
| KR (1) | KR102723164B1 (es) |
| CN (1) | CN111655694B (es) |
| AU (1) | AU2019224410A1 (es) |
| BR (1) | BR112020015729A2 (es) |
| CA (1) | CA3088718A1 (es) |
| IL (1) | IL276160A (es) |
| MX (1) | MX2020008110A (es) |
| RU (1) | RU2020125450A (es) |
| SG (1) | SG11202005926XA (es) |
| TW (1) | TW201936607A (es) |
| WO (1) | WO2019163956A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11141418B1 (en) * | 2018-06-22 | 2021-10-12 | The Board Of Regents, The University Of Texas System | Methods and compositions for KRAS inhibitors |
| WO2021106864A1 (en) * | 2019-11-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Process for the preparation of producing pyrazolo[1,5-a] pyrimidine derivatives |
| CA3220630A1 (en) | 2021-06-02 | 2022-12-08 | Otsuka Pharmaceutical Co., Ltd. | Pyrazolo[1,5-a]pyrimidine compound for the treatment of dermal disorders |
| AU2023279857A1 (en) | 2022-06-03 | 2024-11-14 | Domain Therapeutics | Novel par-2 inhibitors |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025191185A1 (en) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003037900A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazolopyrimidines |
| JP2003286171A (ja) * | 2002-03-28 | 2003-10-07 | Sumitomo Pharmaceut Co Ltd | Ｐａｒ阻害剤 |
| JP2004170323A (ja) * | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| JPWO2005030773A1 (ja) | 2003-09-26 | 2006-12-07 | 大日本住友製薬株式会社 | 新規ピラゾロピリミジン誘導体 |
| MX2012009866A (es) | 2010-02-26 | 2012-09-12 | Mitsubishi Tanabe Pharma Corp | Compuestos pirazolopirimidina y su uso como inhibidores de fosfodiesterasa 10. |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| GB201101517D0 (en) | 2011-01-28 | 2011-03-16 | Proximagen Ltd | Receptor antagonists |
| JP5531066B2 (ja) | 2011-08-24 | 2014-06-25 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物及びｐｄｅ１０阻害剤としてのその使用 |
| HK1225386A1 (zh) * | 2013-09-25 | 2017-09-08 | 沃泰克斯药物股份有限公司 | 用作par-2信號傳導途徑抑制劑的咪唑並噠嗪類 |
| ES2886840T3 (es) * | 2016-08-31 | 2021-12-21 | Eisai R&D Man Co Ltd | Compuesto de pirazolo[1,5-a]pirimidina |
-
2019
- 2019-02-22 EP EP19757272.0A patent/EP3760631B1/en active Active
- 2019-02-22 KR KR1020207022677A patent/KR102723164B1/ko active Active
- 2019-02-22 WO PCT/JP2019/006850 patent/WO2019163956A1/ja not_active Ceased
- 2019-02-22 US US16/965,067 patent/US11312720B2/en active Active
- 2019-02-22 BR BR112020015729-5A patent/BR112020015729A2/pt not_active Application Discontinuation
- 2019-02-22 CA CA3088718A patent/CA3088718A1/en active Pending
- 2019-02-22 MX MX2020008110A patent/MX2020008110A/es unknown
- 2019-02-22 TW TW108105948A patent/TW201936607A/zh unknown
- 2019-02-22 AU AU2019224410A patent/AU2019224410A1/en not_active Abandoned
- 2019-02-22 JP JP2020501065A patent/JP7257376B2/ja active Active
- 2019-02-22 SG SG11202005926XA patent/SG11202005926XA/en unknown
- 2019-02-22 CN CN201980010733.4A patent/CN111655694B/zh active Active
- 2019-02-22 RU RU2020125450A patent/RU2020125450A/ru unknown
-
2020
- 2020-07-20 IL IL276160A patent/IL276160A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3088718A1 (en) | 2019-08-29 |
| US20210107907A1 (en) | 2021-04-15 |
| BR112020015729A2 (pt) | 2020-12-08 |
| EP3760631A4 (en) | 2021-10-20 |
| WO2019163956A1 (ja) | 2019-08-29 |
| TW201936607A (zh) | 2019-09-16 |
| SG11202005926XA (en) | 2020-07-29 |
| EP3760631B1 (en) | 2023-11-08 |
| JP7257376B2 (ja) | 2023-04-13 |
| RU2020125450A (ru) | 2022-03-28 |
| CN111655694A (zh) | 2020-09-11 |
| CN111655694B (zh) | 2023-03-28 |
| KR20200124655A (ko) | 2020-11-03 |
| KR102723164B1 (ko) | 2024-10-30 |
| US11312720B2 (en) | 2022-04-26 |
| EP3760631A1 (en) | 2021-01-06 |
| AU2019224410A1 (en) | 2020-07-09 |
| JPWO2019163956A1 (ja) | 2021-02-04 |
| RU2020125450A3 (es) | 2022-03-28 |
| IL276160A (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008110A (es) | Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma. | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| PH12018500437A1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof | |
| PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| TN2019000133A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12018500605A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2016044641A3 (en) | Carm1 inhibitors and uses thereof | |
| BR112015003380A2 (pt) | composto de pirazolopirimidina | |
| MX338392B (es) | Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| AU2015211852A1 (en) | Heterocyclic sulfonamide derivative and medicine comprising same | |
| SA519401827B1 (ar) | [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه | |
| AU2017319080A1 (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| MX367772B (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| WO2015110491A3 (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
| MX382058B (es) | Hidroxietil sulfonato de inhibidor de proteína cinasa dependiente de ciclina, su forma cristalina y su método de preparación. | |
| MY194711A (en) | Novel annelated phenoxyacetamides | |
| SG11201810725WA (en) | Novel β-lactamase inhibitors | |
| MX2021001116A (es) | Metodos para purificar sulfato de isavuconazonio. | |
| MX379373B (es) | Derivado de sulfonamida heterocíclico y medicina que contiene el mismo. | |
| MX2017009597A (es) | Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100. | |
| AU2015280874A1 (en) | Novel heterocyclic compound | |
| MX381037B (es) | Formas cristalinas y formas de sal de compuestos de 7h-pirrolo [2,3-d]pirimidina y método de preparación de las mismas. |